EP1540012A4 - Polymorphisms for predicting disease and treatment outcome - Google Patents
Polymorphisms for predicting disease and treatment outcomeInfo
- Publication number
- EP1540012A4 EP1540012A4 EP03772163A EP03772163A EP1540012A4 EP 1540012 A4 EP1540012 A4 EP 1540012A4 EP 03772163 A EP03772163 A EP 03772163A EP 03772163 A EP03772163 A EP 03772163A EP 1540012 A4 EP1540012 A4 EP 1540012A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- polymorphisms
- treatment outcome
- predicting disease
- predicting
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10184531A EP2385139A1 (en) | 2002-07-31 | 2003-07-31 | Polymorphisms for predicting disease and treatment outcome |
EP10184438A EP2385137A1 (en) | 2002-07-31 | 2003-07-31 | Polymorphisms for predicting disease and treatment outcome |
EP10184512A EP2385138A1 (en) | 2002-07-31 | 2003-07-31 | Polymorphisms for predicting disease and treatment outcome |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40025002P | 2002-07-31 | 2002-07-31 | |
US40027602P | 2002-07-31 | 2002-07-31 | |
US40024902P | 2002-07-31 | 2002-07-31 | |
US40025302P | 2002-07-31 | 2002-07-31 | |
US400249P | 2002-07-31 | ||
US400250P | 2002-07-31 | ||
US400276P | 2002-07-31 | ||
US400253P | 2002-07-31 | ||
PCT/US2003/024065 WO2004011625A2 (en) | 2002-07-31 | 2003-07-31 | Polymorphisms for predicting disease and treatment outcome |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1540012A2 EP1540012A2 (en) | 2005-06-15 |
EP1540012A4 true EP1540012A4 (en) | 2006-03-22 |
Family
ID=31192379
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10184438A Withdrawn EP2385137A1 (en) | 2002-07-31 | 2003-07-31 | Polymorphisms for predicting disease and treatment outcome |
EP03772163A Withdrawn EP1540012A4 (en) | 2002-07-31 | 2003-07-31 | Polymorphisms for predicting disease and treatment outcome |
EP10184531A Withdrawn EP2385139A1 (en) | 2002-07-31 | 2003-07-31 | Polymorphisms for predicting disease and treatment outcome |
EP10184512A Withdrawn EP2385138A1 (en) | 2002-07-31 | 2003-07-31 | Polymorphisms for predicting disease and treatment outcome |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10184438A Withdrawn EP2385137A1 (en) | 2002-07-31 | 2003-07-31 | Polymorphisms for predicting disease and treatment outcome |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10184531A Withdrawn EP2385139A1 (en) | 2002-07-31 | 2003-07-31 | Polymorphisms for predicting disease and treatment outcome |
EP10184512A Withdrawn EP2385138A1 (en) | 2002-07-31 | 2003-07-31 | Polymorphisms for predicting disease and treatment outcome |
Country Status (6)
Country | Link |
---|---|
US (4) | US7662553B2 (en) |
EP (4) | EP2385137A1 (en) |
JP (1) | JP2005534686A (en) |
AU (1) | AU2003257110A1 (en) |
CA (1) | CA2494262A1 (en) |
WO (1) | WO2004011625A2 (en) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001036686A2 (en) * | 1999-11-15 | 2001-05-25 | University Of Southern California | Genomic polymorphism for predicting therapeutic response |
AU2002241911B9 (en) | 2001-01-19 | 2007-01-25 | Celmed Oncology (Usa), Inc. | Methods to treat autoimmune and inflammatory conditions |
AU2003257110A1 (en) | 2002-07-31 | 2004-02-16 | University Of Southern California | Polymorphisms for predicting disease and treatment outcome |
US20050014165A1 (en) * | 2003-07-18 | 2005-01-20 | California Pacific Medical Center | Biomarker panel for colorectal cancer |
EP1730306A2 (en) * | 2004-03-01 | 2006-12-13 | University of Chicago | Polymorphisms in the epidermal growth factor receptor gene promoter |
EP1781809A1 (en) * | 2004-04-08 | 2007-05-09 | BRAUCH, Hiltrud | Ercc2 polymorphisms |
US20060115827A1 (en) * | 2004-07-01 | 2006-06-01 | University Of Southern California | Genetic markers for predicting disease and treatment outcome |
GB2424886A (en) | 2005-04-04 | 2006-10-11 | Dxs Ltd | Polynucleotide primers against epidermal growth factor receptor and method of detecting gene mutations |
EP1960549A4 (en) * | 2005-11-30 | 2010-01-13 | Univ Southern California | Fc polymorphisms for predicting disease and treatment outcome |
EP1991268A4 (en) * | 2006-03-03 | 2009-08-26 | Univ Southern California | Angiogenesis pathway gene polymorphisms for therapy selection |
US20070218487A1 (en) * | 2006-03-03 | 2007-09-20 | University Of Southern California | Genetic markers for predicting disease and treatment outcome |
EP1991707A4 (en) * | 2006-03-03 | 2012-11-21 | Univ Southern California | Polymorphisms in voltage-gated sodium channel alpha 1-subunit as markers for therapy selection |
WO2007114896A2 (en) | 2006-03-31 | 2007-10-11 | Ordway Research Institute | Prognostic and diagnostic method for cancer therapy |
EP2059615A2 (en) * | 2006-08-17 | 2009-05-20 | Ordway Research Institute, Inc. | Prognostic and diagnostic method for disease therapy |
FR2906532B1 (en) * | 2006-09-28 | 2008-12-12 | Biomerieux Sa | NEW OLIGONUCLEOTIDE BRAND |
US8338109B2 (en) | 2006-11-02 | 2012-12-25 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
WO2008088860A2 (en) | 2007-01-18 | 2008-07-24 | University Of Southern California | Polymorphisms in the egfr pathway as markers for cancer treatment |
WO2008088861A2 (en) | 2007-01-18 | 2008-07-24 | University Of Southern California | Gene polymorphisms predictive for dual tki therapy |
AU2008205544A1 (en) * | 2007-01-18 | 2008-07-24 | University Of Southern California | Gene polymorphisms as predictors of tumor progression and their use in cancer therapy |
WO2008089465A2 (en) * | 2007-01-18 | 2008-07-24 | University Of Southern California | Gene polymorphisms as sex-specific predictors in cancer therapy |
EP2155908A4 (en) * | 2007-05-18 | 2010-12-01 | Univ Southern California | Germline polymorphisms in the angiogenic pathway predict tumor recurrence in cancer therapy |
WO2009009776A2 (en) * | 2007-07-12 | 2009-01-15 | Tragara Pharmaceuticals, Inc. | Patient selection and therapeutic methods using markers of prostaglandin metabolism |
EP2170062A4 (en) | 2007-07-12 | 2010-12-29 | Tragara Pharmaceuticals Inc | Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders |
DE102007036404A1 (en) * | 2007-07-27 | 2009-01-29 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Detection of platinum resistance |
WO2009113989A1 (en) * | 2008-03-14 | 2009-09-17 | Bionumerik Pharmaceuticals, Inc. | Compositions and methods of use of compounds to increase cancer patient survival time |
EP2283148A4 (en) * | 2008-04-25 | 2011-11-30 | Integrated Bioscience Solutions Llc | Cytological methods for detecting cancer |
CA2724346A1 (en) * | 2008-05-15 | 2009-11-19 | University Of Southern California | Ercc-1 expression predicts chemotherapy outcome |
EP2806054A1 (en) | 2008-05-28 | 2014-11-26 | Genomedx Biosciences Inc. | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer |
US10407731B2 (en) | 2008-05-30 | 2019-09-10 | Mayo Foundation For Medical Education And Research | Biomarker panels for predicting prostate cancer outcomes |
GB2467691A (en) | 2008-09-05 | 2010-08-11 | Aueon Inc | Methods for stratifying and annotating cancer drug treatment options |
US10236078B2 (en) | 2008-11-17 | 2019-03-19 | Veracyte, Inc. | Methods for processing or analyzing a sample of thyroid tissue |
US9495515B1 (en) | 2009-12-09 | 2016-11-15 | Veracyte, Inc. | Algorithms for disease diagnostics |
CN104523661A (en) | 2009-02-06 | 2015-04-22 | 南加利福尼亚大学 | Therapeutic compositions comprising monoterpenes |
US9074258B2 (en) | 2009-03-04 | 2015-07-07 | Genomedx Biosciences Inc. | Compositions and methods for classifying thyroid nodule disease |
US8568968B2 (en) * | 2009-04-13 | 2013-10-29 | University Of Southern California | EGFR polymorphisms predict gender-related treatment |
WO2010124239A2 (en) * | 2009-04-24 | 2010-10-28 | University Of Southern California | Genetic polymorphisms associated with clinical outcomes of topoisomerase inhibitor therapy for cancer |
WO2010129934A2 (en) | 2009-05-07 | 2010-11-11 | Veracyte, Inc. | Methods and compositions for diagnosis of thyroid conditions |
EP2311977A1 (en) * | 2009-10-15 | 2011-04-20 | INSERM (Institut National de la Santé et de la Recherche Medicale) | Method for predicting responsiveness of a patient to a chemoradiation treatment |
US10446272B2 (en) | 2009-12-09 | 2019-10-15 | Veracyte, Inc. | Methods and compositions for classification of samples |
US10513737B2 (en) | 2011-12-13 | 2019-12-24 | Decipher Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
DK3435084T3 (en) | 2012-08-16 | 2023-05-30 | Mayo Found Medical Education & Res | PROSTATE CANCER PROGNOSIS USING BIOMARKERS |
US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
EP3770274A1 (en) | 2014-11-05 | 2021-01-27 | Veracyte, Inc. | Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data |
EP3504348B1 (en) | 2016-08-24 | 2022-12-14 | Decipher Biosciences, Inc. | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy |
US11208697B2 (en) | 2017-01-20 | 2021-12-28 | Decipher Biosciences, Inc. | Molecular subtyping, prognosis, and treatment of bladder cancer |
US11873532B2 (en) | 2017-03-09 | 2024-01-16 | Decipher Biosciences, Inc. | Subtyping prostate cancer to predict response to hormone therapy |
WO2018205035A1 (en) | 2017-05-12 | 2018-11-15 | Genomedx Biosciences, Inc | Genetic signatures to predict prostate cancer metastasis and identify tumor agressiveness |
US11217329B1 (en) | 2017-06-23 | 2022-01-04 | Veracyte, Inc. | Methods and systems for determining biological sample integrity |
RU2732336C1 (en) * | 2020-01-14 | 2020-09-15 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Рязанский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации | Method for predicting effectiveness of neoadjuvant chemoradiotherapy in rectal adenocarcinoma |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001036686A2 (en) * | 1999-11-15 | 2001-05-25 | University Of Southern California | Genomic polymorphism for predicting therapeutic response |
WO2004037852A2 (en) * | 2002-10-21 | 2004-05-06 | University Of Medicine And Dentistry Of New Jersey | Thymidylate synthase polymorphisms for use in screening for cancer susceptibility |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8311018D0 (en) | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4998617A (en) | 1986-09-15 | 1991-03-12 | Laura Lupton Inc | Facial cosmetic liquid make up kit |
US5202231A (en) | 1987-04-01 | 1993-04-13 | Drmanac Radoje T | Method of sequencing of genomes by hybridization of oligonucleotide probes |
US6270961B1 (en) | 1987-04-01 | 2001-08-07 | Hyseq, Inc. | Methods and apparatus for DNA sequencing and DNA identification |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
US5256775A (en) | 1989-06-05 | 1993-10-26 | Gilead Sciences, Inc. | Exonuclease-resistant oligonucleotides |
FR2650840B1 (en) | 1989-08-11 | 1991-11-29 | Bertin & Cie | RAPID DETECTION AND / OR IDENTIFICATION OF A SINGLE BASED ON A NUCLEIC ACID SEQUENCE, AND ITS APPLICATIONS |
US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
EP0500727B1 (en) | 1989-11-13 | 1998-01-21 | Children's Medical Center Corporation | Non-invasive method for isolation and detection of fetal dna |
US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
DE69322266T2 (en) | 1992-04-03 | 1999-06-02 | Perkin-Elmer Corp., Foster City, Calif. | SAMPLES COMPOSITION AND METHOD |
US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
US5547835A (en) | 1993-01-07 | 1996-08-20 | Sequenom, Inc. | DNA sequencing by mass spectrometry |
AU687801B2 (en) | 1993-03-19 | 1998-03-05 | Sequenom, Inc. | DNA sequencing by mass spectrometry via exonuclease degradation |
US5593826A (en) | 1993-03-22 | 1997-01-14 | Perkin-Elmer Corporation, Applied Biosystems, Inc. | Enzymatic ligation of 3'amino-substituted oligonucleotides |
US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
US5952172A (en) | 1993-12-10 | 1999-09-14 | California Institute Of Technology | Nucleic acid mediated electron transfer |
US5705336A (en) * | 1995-03-07 | 1998-01-06 | The United States Of America As Represented By The Department Of Health And Human Services | Assay for sensitivity of tumors to DNA-platinating chemotherapy |
US5571676A (en) | 1995-06-07 | 1996-11-05 | Ig Laboratories, Inc. | Method for mismatch-directed in vitro DNA sequencing |
US5968740A (en) | 1995-07-24 | 1999-10-19 | Affymetrix, Inc. | Method of Identifying a Base in a Nucleic Acid |
WO1997046715A1 (en) | 1996-06-03 | 1997-12-11 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Fc receptor polymorphism |
US6248535B1 (en) | 1999-12-20 | 2001-06-19 | University Of Southern California | Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens |
US6716581B2 (en) | 2000-03-31 | 2004-04-06 | University Of Southern California | Manganese superoxide dismutase gene polymorphism for predicting cancer susceptibility |
US7049059B2 (en) | 2000-12-01 | 2006-05-23 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression |
US6518416B1 (en) | 2000-12-01 | 2003-02-11 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 expression |
US6602670B2 (en) | 2000-12-01 | 2003-08-05 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 expression |
US20040265813A1 (en) | 2001-07-05 | 2004-12-30 | Teiji Takechi | Dna arrays for measuring sensitivity to anticancer agent |
DE02782887T1 (en) | 2001-10-19 | 2005-01-13 | Centre Hospitalier Regional et Universitair de Tours | METHODS AND COMPOSITIONS TO EVALUATE ANTIBODY TREATMENT |
AU2003257110A1 (en) | 2002-07-31 | 2004-02-16 | University Of Southern California | Polymorphisms for predicting disease and treatment outcome |
EP1584691A1 (en) * | 2003-01-10 | 2005-10-12 | Fundacion para la Investigacion Clinica y Molecular del Cancer de Pulmon | Device for assaying polymorphisms of gene xpd/ercc2 for the correct administration of chemotherapy for lung cancer |
US9109255B2 (en) | 2004-06-18 | 2015-08-18 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for determining responsiveness to antibody therapy |
US20060115827A1 (en) | 2004-07-01 | 2006-06-01 | University Of Southern California | Genetic markers for predicting disease and treatment outcome |
EP1960549A4 (en) | 2005-11-30 | 2010-01-13 | Univ Southern California | Fc polymorphisms for predicting disease and treatment outcome |
US20070218487A1 (en) | 2006-03-03 | 2007-09-20 | University Of Southern California | Genetic markers for predicting disease and treatment outcome |
EP1991707A4 (en) | 2006-03-03 | 2012-11-21 | Univ Southern California | Polymorphisms in voltage-gated sodium channel alpha 1-subunit as markers for therapy selection |
EP1991268A4 (en) | 2006-03-03 | 2009-08-26 | Univ Southern California | Angiogenesis pathway gene polymorphisms for therapy selection |
AU2008205544A1 (en) | 2007-01-18 | 2008-07-24 | University Of Southern California | Gene polymorphisms as predictors of tumor progression and their use in cancer therapy |
CA2675305A1 (en) | 2007-01-18 | 2008-07-24 | University Of Southern California | Gene polymorphisms in vegf and vegf receptor 2 as markers for cancer therapy |
WO2008089465A2 (en) | 2007-01-18 | 2008-07-24 | University Of Southern California | Gene polymorphisms as sex-specific predictors in cancer therapy |
EP2109686A2 (en) | 2007-01-18 | 2009-10-21 | University Of Southern California | Genetic markers for predicting responsiveness to combination therapy |
WO2008088860A2 (en) | 2007-01-18 | 2008-07-24 | University Of Southern California | Polymorphisms in the egfr pathway as markers for cancer treatment |
WO2008088861A2 (en) | 2007-01-18 | 2008-07-24 | University Of Southern California | Gene polymorphisms predictive for dual tki therapy |
EP2132328A2 (en) | 2007-01-18 | 2009-12-16 | University Of Southern California | Tissue factor promoter polymorphisms |
US9031642B2 (en) | 2013-02-21 | 2015-05-12 | Medtronic, Inc. | Methods for simultaneous cardiac substrate mapping using spatial correlation maps between neighboring unipolar electrograms |
-
2003
- 2003-07-31 AU AU2003257110A patent/AU2003257110A1/en not_active Abandoned
- 2003-07-31 EP EP10184438A patent/EP2385137A1/en not_active Withdrawn
- 2003-07-31 EP EP03772163A patent/EP1540012A4/en not_active Withdrawn
- 2003-07-31 WO PCT/US2003/024065 patent/WO2004011625A2/en active Application Filing
- 2003-07-31 EP EP10184531A patent/EP2385139A1/en not_active Withdrawn
- 2003-07-31 CA CA002494262A patent/CA2494262A1/en not_active Abandoned
- 2003-07-31 US US10/522,664 patent/US7662553B2/en not_active Expired - Fee Related
- 2003-07-31 EP EP10184512A patent/EP2385138A1/en not_active Withdrawn
- 2003-07-31 JP JP2004524265A patent/JP2005534686A/en active Pending
-
2009
- 2009-12-30 US US12/650,323 patent/US20100173922A1/en not_active Abandoned
-
2011
- 2011-10-17 US US13/275,225 patent/US20120122946A1/en not_active Abandoned
-
2013
- 2013-02-01 US US13/757,610 patent/US20130196955A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001036686A2 (en) * | 1999-11-15 | 2001-05-25 | University Of Southern California | Genomic polymorphism for predicting therapeutic response |
WO2004037852A2 (en) * | 2002-10-21 | 2004-05-06 | University Of Medicine And Dentistry Of New Jersey | Thymidylate synthase polymorphisms for use in screening for cancer susceptibility |
Non-Patent Citations (10)
Title |
---|
FOX S H ET AL: "Angiogenesis in normal tissue adjacent to colon cancer.", JOURNAL OF SURGICAL ONCOLOGY. DEC 1998, vol. 69, no. 4, December 1998 (1998-12-01), pages 230 - 234, XP002362465, ISSN: 0022-4790 * |
IACOPETTA B ET AL: "A POLYMORPHISM IN THE ENHANCER REGION OF THE THYMIDYLATE SYNTHASE PROMOTER INFLUENCES THE SURVIVAL OF COLORECTAL CANCER PATIENTS TREATED WITH 5-FLUOROURACIL", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 85, no. 6, 14 September 2001 (2001-09-14), pages 827 - 830, XP001199503, ISSN: 0007-0920 * |
KUNIYASU H ET AL: "Induction of angiogenesis by hyperplastic colonic mucosa adjacent to colon cancer.", AMERICAN JOURNAL OF PATHOLOGY. NOV 2000, vol. 157, no. 5, November 2000 (2000-11-01), pages 1523 - 1535, XP002362464, ISSN: 0002-9440 * |
LENZ HEINZ-JOSEF ET AL: "A 6 base-pair deletion in the 3 UTR of the thymidylate synthase (TS) gene predicts TS mRNA expression in colorectal tumors: A possible candidate gene for colorectal cancer risk", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 43, March 2002 (2002-03-01), & 93RD ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; SAN FRANCISCO, CALIFORNIA, USA; APRIL 06-10, 2002, pages 660, XP001207619, ISSN: 0197-016X * |
LIOTTA L A ET AL: "The microenvironment of the tumour-host interface.", NATURE. 17 MAY 2001, vol. 411, no. 6835, 17 May 2001 (2001-05-17), pages 375 - 379, XP002362466, ISSN: 0028-0836 * |
PARK DAVID J ET AL: "Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer", INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, vol. 17, no. 1, January 2002 (2002-01-01), pages 46 - 49, XP002347623, ISSN: 0179-1958 * |
PULLARKAT S ET AL: "THYMIDYLATE SYNTHASE GENE POLYMORPHISM DETERMINES RESPONSE AND TOXICITY OF 5-FU CHEMOTHERAPY", PHARMACOGENOMICS JOURNAL, NATURE PUBLISHING GROUP, GB, vol. 1, no. 1, 2001, pages 65 - 70, XP001013686, ISSN: 1470-269X * |
SHIROTA Y ET AL: "ERCC1 AND THYMIDYLATE SYNTHASE MRNA LEVELS PREDICT SURVIVAL FOR COLORECTAL CANCER PATIENTS RECEIVING COMBINATION OXALIPLATIN AND FLUOROURACIL CHEMOTHERAPY", JOURNAL OF CLINICAL ONCOLOGY, GRUNE AND STRATTON, NEW YORK, NY, US, vol. 19, no. 23, 1 December 2001 (2001-12-01), pages 4298 - 4304, XP009002481, ISSN: 0732-183X * |
ULRICH ET AL: "Searching expressed sequence tag databases: discovery and confirmation of a common polymorphism in the thymidylate synthase gene", CANCER EPIDEMIOLOGY, BIOMARKERS AND PREVENTION, AMERICAN ASSOCIATION FOR CANCER RESEARCH,, US, vol. 9, no. 12, December 2000 (2000-12-01), pages 1381 - 1385, XP002979555, ISSN: 1055-9965 * |
VILLAFRANCA E ET AL: "POLYMORPHISMS OF THE REPEATED SEQUENCES IN THE ENHANCER REGION OF THE THYMIDYLATE SYNTHASE GENE PROMOTER MAY PREDICT DOWNSTAGING AFTER PREOPERATIVE CHEMORADIATION IN RECTAL CANCER", JOURNAL OF CLINICAL ONCOLOGY, GRUNE AND STRATTON, NEW YORK, NY, US, vol. 19, no. 6, 15 March 2001 (2001-03-15), pages 1779 - 1786, XP008033687, ISSN: 0732-183X * |
Also Published As
Publication number | Publication date |
---|---|
US7662553B2 (en) | 2010-02-16 |
US20100173922A1 (en) | 2010-07-08 |
EP2385138A1 (en) | 2011-11-09 |
EP2385139A1 (en) | 2011-11-09 |
US20130196955A1 (en) | 2013-08-01 |
US20120122946A1 (en) | 2012-05-17 |
AU2003257110A8 (en) | 2004-02-16 |
AU2003257110A1 (en) | 2004-02-16 |
EP2385137A1 (en) | 2011-11-09 |
CA2494262A1 (en) | 2004-02-05 |
EP1540012A2 (en) | 2005-06-15 |
US20060094012A1 (en) | 2006-05-04 |
JP2005534686A (en) | 2005-11-17 |
WO2004011625A3 (en) | 2004-11-11 |
WO2004011625A2 (en) | 2004-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003257110A8 (en) | Polymorphisms for predicting disease and treatment outcome | |
EP1774039A4 (en) | Genetic markers for predicting disease and treatment outcome | |
GB0201850D0 (en) | Therapeutic treatment | |
GB0216321D0 (en) | Therapeutic treatment | |
AU2003290548A8 (en) | Prevention and treatment of synucleinopathic disease | |
IL165575A0 (en) | System for treating obesity and implant therefor | |
EP1960549A4 (en) | Fc polymorphisms for predicting disease and treatment outcome | |
AU2002325435A8 (en) | Medication and method for treating pathological syndrome | |
HK1078784A1 (en) | Therapeutic treatment | |
EP1567198A4 (en) | Materials and methods for treating ocular-related disorders | |
AU2003266291A8 (en) | Single nucleotide polymorphisms predicting adverse drug reactions and drug efficacy in cardiovascular disease | |
GB0223367D0 (en) | Therapeutic treatment | |
IL165242A0 (en) | Treatment for diabetes | |
GB2388557B (en) | Treatment system | |
EP1576109A4 (en) | Methods and compositions for categorizing patients | |
AU2003223780A8 (en) | Treatment for pompe disease | |
GB0210464D0 (en) | Therapeutic treatment | |
AU2003301348A8 (en) | Compositions and methods for diagnosing and treating autoimmune disease | |
AU2003277202A8 (en) | Methods for diagnosing bone turnover disease | |
AU2003201159A8 (en) | Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy | |
GB2385333B (en) | Plate treatment | |
EP1569928A4 (en) | Therapeutic compounds and methods | |
AU2003248679A8 (en) | Treating disease using radium-225 | |
GB0229139D0 (en) | Gene polymorphisms | |
AU2003297912A8 (en) | Methods for screening compounds for use in the treatment of disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050202 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20060203 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: PARK, DAVID, (JONG-HAN) Inventor name: STOEHLMACHER, JAN Inventor name: LENZ, HEINZ-JOSEF |
|
17Q | First examination report despatched |
Effective date: 20070821 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20110607 |